SCHEMBL4491165

SCHEMBL4491165

CCOC(=O)c1c[nH]cc1-c1ccc(N)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.55
HSD17B10 Q99714 5/20 0.55
PRKCZ Q05513 4/20 0.55
RAB9A P51151 4/20 0.55
SMN1; SMN2 Q16637 4/20 0.55
MEN1 O00255 3/20 0.55
KMT2A Q03164 3/20 0.55
MAPT P10636 3/20 0.55
NPC1 O15118 3/20 0.55
LMNA P02545 2/20 0.55
GAA P10253 2/20 0.55
ALOX15 P16050 2/20 0.55
CYP1A2 P05177 1/20 0.54
CYP3A4 P08684 1/20 0.54
MAOA P21397 1/20 0.54
JAK2 O60674 5/20 0.53
JAK3 P52333 5/20 0.53
TSHR P16473 1/20 0.46
HPGD P15428 3/20 0.42
PRKCI P41743 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2673120 0.88 ALDH1A1 (0.50) ALDH1A1HSD17B10RAB9ASMN1; SMN2MEN1
SCHEMBL6976375 0.85 TSHR (0.46) ALDH1A1HSD17B10PRKCZRAB9ASMN1; SMN2
SCHEMBL6164247 0.85 HTT (0.50) ALDH1A1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL8665022 0.85 PRKCZ (0.52) ALDH1A1HSD17B10PRKCZRAB9ASMN1; SMN2
SCHEMBL4042415 0.84 TSHR (0.58) ALDH1A1HSD17B10RAB9ASMN1; SMN2MEN1
SCHEMBL13712889 0.83 GAA (0.47) ALDH1A1HSD17B10PRKCZSMN1; SMN2MAPT
SCHEMBL328001 0.82 TSHR (0.44) ALDH1A1HSD17B10PRKCZRAB9ASMN1; SMN2
SCHEMBL276323 0.80 AR (0.56) PRKCZRAB9ASMN1; SMN2MAPTGAA
SCHEMBL27971326 0.80 PRKCZ (0.56) ALDH1A1HSD17B10PRKCZRAB9ASMN1; SMN2
SCHEMBL7441914 0.80 ALDH1A1 (0.61) ALDH1A1HSD17B10PRKCZRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2465505-A1 Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis Bayer HealthCare LLC (US) 2012-06-20 EP disclosed
US-7592365-B2 Substituted pyrroles, compositions containing same, method for making same and use thereof AVENTIS PHARMA S.A. (FR) 2009-09-22 US disclosed
US-20080167368-A1 Substituted Pyrroles, Compositions Containing Same, Method for Making Same and Use Thereof AVENTIS PHARMA S.A. (FR) 2008-07-10 US disclosed
WO-2007064842-A2 SYNTHESIS OF CHLORINS AND PHORBINES WITH ENHANCED RED SPECTRAL FEATURES NORTH CAROLINA STATE UNIVERSITY (US) 2007-06-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167368-A1 Substituted Pyrroles, Compositions Containing Same, Method for Making Same and Use Thereof PRMT1, ADPRS, RRM2B ALDH1A1 282/4885HSD17B10 2764/4885PRKCZ 4341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.